HEALTH
## NHS Scotland’s Weight Loss Jab Access Limited to Under 800 Patients, BBC Investigation Reveals
**Edinburgh, Scotland** – Fewer than 800 individuals across Scotland have received weight loss injections through the National Health Service (NHS), a BBC investigation has revealed, highlighting a stark disparity in access to these new-generation treatments. The findings underscore a significant “postcode lottery,” with only five out of Scotland’s 14 health boards currently offering the treatment specifically for chronic weight management.
The limited uptake comes despite the growing recognition of GLP-1 receptor agonists – such as Wegovy and Ozempic (off-label for weight loss) – as crucial tools in the fight against obesity, a major public health challenge across the nation. These medications work by regulating appetite and promoting satiety, offering a significant advancement beyond traditional dietary and lifestyle interventions alone.
The BBC’s findings suggest a fragmented approach to the rollout of these potentially life-changing treatments. While national guidance from the Scottish Medicines Consortium (SMC) has approved some of these drugs for use in specific patient groups, local commissioning decisions and resource availability appear to be creating substantial barriers to access.
For patients struggling with obesity, the current situation means that their geographical location significantly dictates their ability to receive NHS-funded support. Those residing within the nine health boards not offering the treatment specifically for weight loss are effectively excluded, irrespective of their clinical need or eligibility under national guidelines.
Experts have consistently highlighted obesity as a complex chronic disease requiring comprehensive, multi-faceted treatment approaches. The limited availability of these advanced pharmacological interventions on the NHS raises questions about equitable access to care and Scotland’s strategy for tackling its rising obesity rates.
The Scottish Government and NHS Scotland have yet to comment directly on the BBC’s specific findings, but the data is likely to intensify calls for a more uniform and robust national strategy to ensure that all eligible patients can access clinically recommended weight loss treatments, irrespective of where they live.
